RNACHealthcare · BiotechnologyThe 7 Wall Street analysts covering Cartesian Therapeutics, Inc. hold a median 12-month price target of $39 — +462.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 3 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cartesian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RNAC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +462.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 29 Sept 2026 | Needham | Reiterates | Buy | $40 |
| 18 Aug 2026 | Wedbush | Reiterates | Outperform | — |
| 18 Aug 2026 | Wedbush | Reiterates | Outperform | $38 |
| 10 June 2026 | Wedbush | Reiterates | Outperform | — |
| 10 June 2026 | Wedbush | Reiterates | Outperform | $38 |
| 9 June 2026 | BTIG | Reiterates | Buy | $44 |
| 9 June 2026 | BTIG | Reiterates | Buy | — |
| 9 June 2026 | Needham | Reiterates | Buy | $40 |
| 9 June 2026 | Needham | Reiterates | Buy | — |
| 27 May 2026 | Wedbush | Reiterates | Outperform | — |
| 26 May 2026 | Needham | Maintains | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 May 2026 | Wedbush | Reiterates | Outperform | — |
| 10 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Mar 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 9 Mar 2026 | Needham | Reiterates | Buy | — |
| 9 Jan 2026 | Needham | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RNAC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Cartesian Therapeutics, Inc. returned −11.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 3% of US stocks
Cheaper than 95% of US stocks
Cheaper than 70% of US stocks
Higher than 1% of US stocks
Higher than 36% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 96% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cartesian Therapeutics, Inc. has a market value of $191.8M and an enterprise value of $108.1M.
Revenue in the twelve months to 30 June 2026: $1.5M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$151.9M, a −10283.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$78.6M.
Trailing P/E: 2.0×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Cartesian Therapeutics, Inc. employs 75 people — $20K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cartesian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cartesian Therapeutics announced an employment inducement award for one new employee on November 3, 2026.
Why it matters — RNAC watchers may note the company’s employee-related compensation disclosure.
Seeking Alpha maintains a Buy rating on Cartesian, citing progress in Descartes-08 programs and the WestGene licensing agreement. Topline phase 3 AURORA results are expected in Q1 2027, a potential BLA filing in mid-2027, and initial data from the in vivo CAR-T approach in H1 2027.
Why it matters — RNAC watchers may track the upcoming AURORA results and early data from its expanded programs as clinical and partnership milestones.
Cartesian Therapeutics announced it granted inducement awards to four new employees on October 1, 2026, consisting of options to purchase an aggregate of 121,900 shares of common stock at an exercise price of $7.22. The options, approved by the board of directors, vest over a multi-year schedule and have a ten-year term, granted under Nasdaq Rule 5635(c)(4) as an employment inducement.
Why it matters — A RNAC watcher would note this as a routine equity-based inducement action tied to new hires, reflecting standard compensation practice with no immediate operational or financial impact.
Cartesian Therapeutics announced additional retreatment data for its investigational therapy Descartes-08 in patients with myasthenia gravis. The data showed improvement in mean change from baseline on the MG-ADL scale, including a mean reduction of 6.6 points at Month 12 following retreatment, highlighting deep and durable responses.
Why it matters — RNAC watchers would care because the data reinforce the durability and depth of Descartes-08's responses in myasthenia gravis, a key clinical and regulatory development for the company's pipeline.
Cartesian Therapeutics announced the granting of employment inducement awards to three new employees. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases.
Why it matters — This signals new hiring at Cartesian, which may be relevant for RNAC watchers tracking the company's personnel and operational developments.
The 7 Wall Street analysts covering Cartesian Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $16 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Cartesian Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cartesian Therapeutics, Inc. 33 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Cartesian Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +462.9% from the last close, and Ticker Nerd's factor model ranks Cartesian Therapeutics, Inc. 33 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cartesian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $44 over the next 12 months.
Cartesian Therapeutics, Inc. returned -11.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Cartesian Therapeutics Announces New Employment Inducement Grant". Cartesian Therapeutics announced an employment inducement award for one new employee on November 3, 2026.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.
CEO Dr. Carsten Brunn Ph.D. · 75 employees · United States · https://www.cartesiantherapeutics.com
